Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Feldman

Showing results (1001-1010 of 1,068) with videos related to

Pageof 107
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2017
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3Yong-Chen Lu, Linda L Parker, Tangying Lu, et al.
Cancer Research Communications|July 31, 2025
GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor ProfilingHassan Ghani, Anthony Helmstetter, Jennifer R Ribeiro, et al.
Nature Communications|October 6, 2024
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potencyJustin A Guerrero, Dorota D Klysz, Yiyun Chen, et al.
Blood|December 14, 2011
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsJames N Kochenderfer, Mark E Dudley, Steven A Feldman, et al.
JCI Insight|December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapyChristopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast CancerYasmine Assadipour, Nikolaos Zacharakis, Jessica S Crystal, et al.
Blood Cancer Discovery|December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeHrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.
Seminars in Vascular Surgery|November 22, 2022
The art of peer review: Guidelines to become a credible and constructive peer reviewerM Libby Weaver, Rachael Sundland, Alexandra M Adams, et al.
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanomaLing Zhang, Richard A Morgan, Joal D Beane, et al.
Pageof 107

Showing results (1001-1010 of 1,068) with videos related to

Sort By:
Pageof 107
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2017
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3Yong-Chen Lu, Linda L Parker, Tangying Lu, et al.
Cancer Research Communications|July 31, 2025
GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor ProfilingHassan Ghani, Anthony Helmstetter, Jennifer R Ribeiro, et al.
Nature Communications|October 6, 2024
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potencyJustin A Guerrero, Dorota D Klysz, Yiyun Chen, et al.
Blood|December 14, 2011
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsJames N Kochenderfer, Mark E Dudley, Steven A Feldman, et al.
JCI Insight|December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapyChristopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast CancerYasmine Assadipour, Nikolaos Zacharakis, Jessica S Crystal, et al.
Blood Cancer Discovery|December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeHrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.
Seminars in Vascular Surgery|November 22, 2022
The art of peer review: Guidelines to become a credible and constructive peer reviewerM Libby Weaver, Rachael Sundland, Alexandra M Adams, et al.
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanomaLing Zhang, Richard A Morgan, Joal D Beane, et al.
Pageof 107